Gene Expression Of The BRMS1 (Breast Cancer Metastasis Suppressor 1) In Laryngeal Squamous Cell Carcinoma

IntroductionLaryngeal squamous cell carcinoma (LSCC) is a common malignant tumor in Northern China. It is usually squamous in type and arises in three locations;supraglottic, glottic and subglottic. Especially, the type supraglottic cancer is relatively high, it has been attributed to cervical lymph node metastasis. In LSCC,lymph node metastasis is the most important event in the failure of the treatment of LSCC. Therefore,it is a major goal to identify the molecular mechanisms of invasion and metastasis of the LSCC.Recent molecular biological studies have clearly indicated that metastasis is a complex series of events that involves several gene products,the gene BRMSl (breast cancer metastasis suppressor 1 ) is a recently identified novel candidate metastasis suppressor gene. Decreased BRMSl expression has been observed in several common tumors, including breast cancer, melanoma and others. There was still no report on the relationship between the BRMSl and tumorgenesis and/or development of laryngeal carcinoma. We made the experiment to observe the gene expression differences of BRMSl between fresh laryngeal cancer tissues and their surrounding normal laryngeal mucosa . It was examined by reverse transcription polymerase chain reaction (RT -PCR) at molecule level. Our aim to look for the molecular marker for early diagnosis and predicting of aggressive and metastasis potential and assessing the clinical stage of primary LSCC.Experimental MaterialsThe 56 laryngeal carcinoma fresh samples were analyzed and normal muco-sa that was furthest from the tumor specimen. All subjects were the admitted patients for operative treatment in the ENT department of the first clinical Medical University between December, 2004 to June, 2005 . Of them, there were 20 su-praglotti laryngeal carcinomas patients with cervical lymph node metastasis, 20 supraglotti laryngeal carcinomas patients with cervical lymph node - negative metastasi, 16 glotti carcinoma with cervical lymph node - negative metastasis and their surrounding normal laryngeal mucosa . All of the patients had not received either chemotherapy or radiotherapy before surgery. The pathological results were all squamous cell carcinoma. The samples were resected and snap - frozen in liquid nitrogen, immediately after surgical resection . Specimens were stored atExperimental MethodsWe applied RT - PCR technique to detect the gene BRMSl expression at level of molecule. All statstical analyses were performed by SPSS version 10.0. to do the calculations . P <0.05 were considered to be statistically significant.Result1. Expression of BRMSl mRNA in laryngeal carcinoma and normal mucosa: 26 of 56 (46.4% )laryngeal carcinoma are BRMSl positive expression, 52 of 56 (92.8%) normal mucosa are BRMSl positive expression,BRMSl mRNA positive expression rates in laryngeal carcinoma is lower than those in normal mucosa, it has very remarkable difference in statistics( P <0. 01) . Specific value of between BRMSl and (3 - actinn is 0. 99 ±0. 54 in laryngeal carcinoma , specific value of between BRMSl and (3 - actin is 1. 22 ±0. 49 in normal mucosa, expression quantity of BRMSl in laryngeal carcinoma is obvious lower than those in normal mucosa, it has very remarkable difference in statistics (p <0.01).2. Relation between BRMSl mRNA and characteristic of clinical pathology in laryngeal carcinoma;The gene expression of BRMSl was not different in different stages in laryngeal glottic cancers ( P >0. 05 ) , but correlated to the dif-ferentiation and lymph node metastasis ( P<0. 05). There was correlation between BRMSl gene expression and the stage , differentiation and lymph node metastasis in the laryngeal supraglottic cancers ( P<0.05 ) .Conclusions1 . Expression of gene BRMSl mRNA in laryngeal carcinoma were lower than those in normal mucosa. Quantitative and qualitative expression of gene BRMSl mRNA in laryngeal carcinoma are consistent.2. There was a correlation between the decreased expression of BRMSl with pathological grade and lymph node metastases, and BRMSl may become one of the molecular marker for early diagnosis and predicting of aggressive and metastasis potential and assessing the clinical stage of primary LSCC.